Abstract
Background and Aims:
Treatment of recurrent platinum-resistant ovarian cancer remains challenging due to the development of chemo-resistance.
Cabazitaxel is a new taxane that has demonstrated effect in prostatic cancer patients resistant to Docetaxel. Therefore, it could be anticipated that it might also have an effect on chemo-resistant ovarian cancer.
The presented results originate from the protocol Cabazitaxel vs. Tocotrienol in patients with Recurrent Ovarian Cancer after failure of standard therapy - A phase 2 randomized open-label study. EudraCT number: 2015-002296-18. Tocotrienol failed to reach its primary endpoint at time of interim analysis and the protocol was continued for cabazitaxel only.
Methods:
Twenty six patients with chemotherapy-resistant epithelial ovarian cancer, fallopian tubal or peritoneal cancer were treated with cabazitaxel at a dose of 25 mg/m2, day 1 q3w, until progression or inacceptable toxicity in the period from September 2015 – April 2018. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was prescribed to all patients.
Two patients are still receiving treatment with cabazitaxel.
Results:
At time of referral for cabazitaxel treatment, patients had received a median of 3 previous chemotherapy regimens (range 2-8). The median number of cabazitaxel infusions was 4.0 (range 1-18). In general, cabazitaxel was well tolerated in patients with good performance status.
In an intention- to- treat analysis, median PFS was 3.9 months (95% C.I; 1.9-5.2) using the combination of CA125 or RECIST (whichever came first). Median OS was 8.9 months (95% C.I; 7.0-10.9). The fraction of patients alive and without progression after three months of treatment was 13/26 patients (50%). Partial response (PR), evaluated by RECIST, was seen in 4/26 patients (15%). The response was confirmed by another scan in 3/26 patients (11.5%). A response rate of 46% (12/26) was detected according to the GCIG CA125 criteria.
Conclusions:
Our data show that cabazitaxel holds promise as a new drug in ovarian cancer. In general the toxicity was manageable.
Treatment of recurrent platinum-resistant ovarian cancer remains challenging due to the development of chemo-resistance.
Cabazitaxel is a new taxane that has demonstrated effect in prostatic cancer patients resistant to Docetaxel. Therefore, it could be anticipated that it might also have an effect on chemo-resistant ovarian cancer.
The presented results originate from the protocol Cabazitaxel vs. Tocotrienol in patients with Recurrent Ovarian Cancer after failure of standard therapy - A phase 2 randomized open-label study. EudraCT number: 2015-002296-18. Tocotrienol failed to reach its primary endpoint at time of interim analysis and the protocol was continued for cabazitaxel only.
Methods:
Twenty six patients with chemotherapy-resistant epithelial ovarian cancer, fallopian tubal or peritoneal cancer were treated with cabazitaxel at a dose of 25 mg/m2, day 1 q3w, until progression or inacceptable toxicity in the period from September 2015 – April 2018. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was prescribed to all patients.
Two patients are still receiving treatment with cabazitaxel.
Results:
At time of referral for cabazitaxel treatment, patients had received a median of 3 previous chemotherapy regimens (range 2-8). The median number of cabazitaxel infusions was 4.0 (range 1-18). In general, cabazitaxel was well tolerated in patients with good performance status.
In an intention- to- treat analysis, median PFS was 3.9 months (95% C.I; 1.9-5.2) using the combination of CA125 or RECIST (whichever came first). Median OS was 8.9 months (95% C.I; 7.0-10.9). The fraction of patients alive and without progression after three months of treatment was 13/26 patients (50%). Partial response (PR), evaluated by RECIST, was seen in 4/26 patients (15%). The response was confirmed by another scan in 3/26 patients (11.5%). A response rate of 46% (12/26) was detected according to the GCIG CA125 criteria.
Conclusions:
Our data show that cabazitaxel holds promise as a new drug in ovarian cancer. In general the toxicity was manageable.
| Originalsprog | Dansk |
|---|---|
| Publikationsdato | 16. sep. 2018 |
| Status | Udgivet - 16. sep. 2018 |
| Begivenhed | 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018) - Kyoto, Japan Varighed: 14. sep. 2018 → 16. sep. 2018 https://igcs2018.com/ |
Konference
| Konference | 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018) |
|---|---|
| Land/Område | Japan |
| By | Kyoto |
| Periode | 14/09/2018 → 16/09/2018 |
| Internetadresse |
Bibliografisk note
Abstract 054Poster presentation
Citationsformater
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver